Head and Neck Cancer - Clinical Trial (07-06-118)
A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-containing therapy with a cross-over period for progressing patients
Protocol ID
Protocol Description
BIBW 2992 is an experimental drug. It belongs to a group of drugs that can affect the function of special proteins called growth factor receptors that are found on the surface of many cancer cells. The particular growth factors that BIBW 2992 will fit are called EFG and HER2. When these receptors are stimulated, the growth of the cancer cells bearing the receptors is accelerated. In contrast, BIBW 2992 is thought to turn off the function of the EGF and HER2 receptors, leading to slowing of growth and even causing some of these cancer cells to die.
Ths purpose of this study is to see if BIBW 2992 is effective and safe in treating head and neck cancer that is recurrent or has spread. In this study, BIBW 2992 will be compared to cetuximab. The purpose is also to see if BIBW 2992 is effective and safe after the cancer no longer responds to cetuximab.
Eligibility Criteria
Patients with head and neck cancer
Primary Investigator(s)
- Bhoomi Mehrotra, MD